Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.74 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.74 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.64 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.64 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.64 |
| ▸ | AKT1 | P31749 | 5/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.37 |
| ▸ | PRKACA | P17612 | 3/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.37 |
| ▸ | PKN2 | Q16513 | 3/20 | 0.37 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.37 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.37 |
| ▸ | STK17A | Q9UEE5 | 3/20 | 0.37 |
| ▸ | DYRK3 | O43781 | 2/20 | 0.37 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.37 |
| ▸ | PIM1 | P11309 | 2/20 | 0.37 |
| ▸ | CLK2 | P49760 | 2/20 | 0.37 |
| ▸ | PRKX | P51817 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL905209 | 1.00 | CHRNB2 (0.74) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL905210 | 1.00 | CHRNB2 (0.74) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL1421800 | 1.00 | CHRNB2 (0.74) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL621496 | 0.86 | CHRNB2 (0.78) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL620296 | 0.86 | CHRNB2 (0.78) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL617912 | 0.86 | CHRNB2 (0.78) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL621495 | 0.86 | CHRNB2 (0.78) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL617913 | 0.86 | CHRNB2 (0.78) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL620297 | 0.86 | CHRNB2 (0.78) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Ispronicline SCHEMBL366585 | 0.85 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160022658-A1 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | ABBVIE INC (US) | 2016-01-28 | — | — | US | claimed |
| EP-2101763-B1 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | ABBOTT LAB (US) | 2012-07-18 | — | — | EP | claimed |
| EP-2226074-A2 | Pharmaceutical compositions and their methods of use | Abbott Laboratories (US) | 2010-09-08 | — | — | EP | claimed |
| EP-2101763-A2 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | Abbott Laboratories (US) | 2009-09-23 | — | — | EP | claimed |
| US-20090221648-A1 | COMPOSITIONS FOR TREATMENT OF COGNITIVE DISORDERS | ABBOTT LABORATORIES (US) | 2009-09-03 | — | — | US | claimed |
| WO-2009082698-A1 | COMPOSITIONS FOR TREATMENT OF COGNITIVE DISORDERS | ABBOTT LABORATORIES (US) | 2009-07-02 | — | — | WO | claimed |
| US-20080167286-A1 | Pharmaceutical compositions and their methods of use | ABBOTT LABORATORIES (US) | 2008-07-10 | — | — | US | claimed |
| WO-2008073942-A2 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | ABBOTT LABORATORIES (US) | 2008-06-19 | — | — | WO | claimed |
| US-20160022658-A1 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | ABBVIE INC (US) | 2016-01-28 | — | — | US | disclosed |
| EP-2974727-A1 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | Abbvie Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-9186407-B2 | Pharmaceutical compositions and their methods of use | ABBVIE INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-9040568-B2 | Pharmaceutical compositions for the treatment of pain | ABBVIE INC. (US) | 2015-05-26 | — | — | US | disclosed |
| EP-2119476-B1 | Amide derivatives as positive allosteric modulators and methods of use thereof | ABBVIE INC (US) | 2014-03-19 | — | — | EP | disclosed |
| US-8486979-B2 | Analgesics; central nervous system disorders; attentiondeficit disorders;cognition activators; bipolar disorders; Alzheimer's disease; Down's syndrome; brain disorders | ABBVIE INC. (US) | 2013-07-16 | — | — | US | disclosed |
| EP-2101763-A2 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | Abbott Laboratories (US) | 2009-09-23 | — | — | EP | disclosed |
| US-20090221648-A1 | COMPOSITIONS FOR TREATMENT OF COGNITIVE DISORDERS | ABBOTT LABORATORIES (US) | 2009-09-03 | — | — | US | disclosed |
| WO-2009082698-A1 | COMPOSITIONS FOR TREATMENT OF COGNITIVE DISORDERS | ABBOTT LABORATORIES (US) | 2009-07-02 | — | — | WO | disclosed |
| US-20080269236-A1 | Novel 1,2,4 Oxadiazole Compounds and Methods of Use Thereof | ABBOTT LABORATORIES (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080167286-A1 | Pharmaceutical compositions and their methods of use | ABBOTT LABORATORIES (US) | 2008-07-10 | — | — | US | disclosed |
| WO-2008073942-A2 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | ABBOTT LABORATORIES (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269236-A1 | Novel 1,2,4 Oxadiazole Compounds and Methods of Use Thereof | OXA1L, CYP11B2, CYP1B1 | CHRNB2 3741/4885CHRNA4 4109/4885CHRNB4 3866/4885 |
| US-20080167286-A1 | Pharmaceutical compositions and their methods of use | CHRNA4, CHRNB4, CHRNA5 | CHRNB2 5/4885CHRNA4 1/4885CHRNB4 2/4885 |
| US-20090221648-A1 | COMPOSITIONS FOR TREATMENT OF COGNITIVE DISORDERS | CHRNA4, CHRNA5, CHRNA3 | CHRNB2 12/4885CHRNA4 1/4885CHRNB4 6/4885 |
| US-20160022658-A1 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | CHRNA4, CHRNB4, CHRNA5 | CHRNB2 5/4885CHRNA4 1/4885CHRNB4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.